Epigenetic <it>CRBP </it>downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer
Arapshian Alice, Bertran Silvina, Kuppumbatti Yuvarani S and 2 more
Molecular Cancer · 2004
doi:10.1186/1476-4598-3-13 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>The cellular retinol binding protein I gene (<it>CRBP</it>) is downregulated in a subset of human breast cancers and in MMTV-Myc induced mouse mammary tumors. Functional studies suggest that <it>CRBP </it>downregulation contributes to breast tumor progression. What is the mechanism underlying <it>CRBP </it>downregulation in cancer? Here we investigated the hypothesis that <it>CRBP </it>is epigenetically silenced through DNA hypermethylation in human and mouse breast cancer.</p> <p>Results</p> <p>Bisulfite sequencing of <it>CRBP </it>in a panel of 6 human breast cancer cell lines demonstrated that, as a rule, <it>CRBP </it>hypermethylation is closely and inversely related to <it>CRBP </it>expression and identified one exception to this rule. Treatment with 5-azacytidine, a DNA methyltransferase inhibitor, led to <it>CRBP </it>reexpression, supporting the hypothesis that <it>CRBP </it>hypermethylation is a proximal cause of <it>CRBP </it>silencing. In some cells <it>CRBP </it>reexpression was potentiated by co-treatment with retinoic acid, an inducer of <it>CRBP</it>, and trichostatin A, a histone deacetylase inhibitor. Southern blot analysis of a small panel of human breast cancer specimens identified one case characterized by extensive <it>CRBP </it>hypermethylation, in association with undetectable CRBP mRNA and protein. Bisulfite sequencing of <it>CRBP </it>in MMTV-Myc and MMTV-Neu/NT mammary tumor cell lines extended the rule of <it>CRBP </it>hypermethylation and silencing (both seen in MMTV-Myc but not MMTV-Neu/NT cells) from human to mouse breast cancer and suggested that <it>CRBP </it>hypermethylation is an oncogene-specific event.</p> <p>Conclusion</p> <p><it>CRBP </it>hypermethylation appears to be an evolutionarily conserved and principal mechanism of <it>CRBP </it>silencing in breast cancer. Based on the analysis of transgenic mouse mammary tumor cells, we hypothesize that <it>CRBP </it>silencing in human breast cancer may be associated with a specific oncogenic signature.</p>
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.